Neutrophilic Panniculitis in a Pediatric Patient Receiving Ponatinib

Ponatinib is a tyrosine kinase inhibitor used in children with chronic myeloid leukemia. We report a case of neutrophilic panniculitis following ponatinib administration in a child. With the expanded use of immunomodulatory medications in the pediatric population, this report aims to expand knowledge regarding potential drug-related adverse events and the inclusion of ponatinib-related adverse events in the differential diagnosis of neutrophilic panniculitis.